Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease

NCT01152216 is registered in ClinicalTrials.gov with Medivation, Inc. as lead sponsor.

NCT NCT01152216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01152216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease
Lead sponsor
Medivation, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2010
Completion date
Not reported
Enrollment
672 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease